Alphatec (NASDAQ:ATEC) Stock Price Target Cut by JPMorgan Chase & Co.

Alphatec (NASDAQ:ATEC) had its price objective decreased by analysts at JPMorgan Chase & Co. from $16.00 to $15.00 in a research report issued on Friday, Benzinga reports. The firm currently has an “overweight” rating on the medical technology company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 113.07% from the stock’s previous close.

ATEC has been the subject of a number of other research reports. Needham & Company LLC dropped their target price on Alphatec from $14.00 to $12.00 and set a “buy” rating for the company in a report on Friday. Wall Street Zen lowered Alphatec from a “buy” rating to a “hold” rating in a report on Sunday, October 11th. TD Cowen lowered their price target on Alphatec from $13.00 to $10.00 and set a “buy” rating for the company in a research report on Friday. Wells Fargo & Company lowered their price target on Alphatec from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alphatec in a research note on Monday, August 3rd. Twelve investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Alphatec presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.60.

Alphatec Trading Down 38.1%

Shares of NASDAQ:ATEC traded down $4.33 during trading on Friday, reaching $7.04. The company’s stock had a trading volume of 27,294,109 shares, compared to its average volume of 3,029,589. The stock has a market capitalization of $1.09 billion, a PE ratio of -9.92 and a beta of 0.78. Alphatec has a 12 month low of $6.81 and a 12 month high of $23.29. The firm’s 50 day simple moving average is $10.18 and its two-hundred day simple moving average is $10.67.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Thursday, October 29th. The medical technology company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 13.49%. The company had revenue of $221.17 million for the quarter, compared to the consensus estimate of $225.16 million. During the same period in the previous year, the firm earned $0.03 earnings per share. The company’s revenue was up 12.6% compared to the same quarter last year. Research analysts anticipate that Alphatec will post -0.45 EPS for the current fiscal year.

Insider Activity at Alphatec

In other news, General Counsel Tyson Marshall sold 8,168 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $9.65, for a total value of $78,821.20. Following the sale, the general counsel directly owned 630,398 shares in the company, valued at approximately $6,083,340.70. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Patrick Miles purchased 115,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were acquired at an average cost of $8.81 per share, with a total value of $1,013,150.00. Following the completion of the purchase, the chief executive officer directly owned 5,893,551 shares in the company, valued at $51,922,184.31. The trade was a 1.99% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 13.48% of the stock is owned by insiders.

Hedge Funds Weigh In On Alphatec

A number of large investors have recently bought and sold shares of ATEC. State of Wyoming boosted its position in Alphatec by 87.7% in the 3rd quarter. State of Wyoming now owns 30,666 shares of the medical technology company’s stock valued at $316,000 after buying an additional 14,328 shares during the period. Sterling Capital Management LLC grew its stake in Alphatec by 841.5% in the 3rd quarter. Sterling Capital Management LLC now owns 4,105 shares of the medical technology company’s stock worth $42,000 after acquiring an additional 3,669 shares in the last quarter. Kopp Family Office LLC increased its position in shares of Alphatec by 0.4% during the third quarter. Kopp Family Office LLC now owns 330,266 shares of the medical technology company’s stock worth $3,408,000 after acquiring an additional 1,303 shares during the period. AA Financial Advisors LLC increased its position in shares of Alphatec by 140.5% during the third quarter. AA Financial Advisors LLC now owns 48,094 shares of the medical technology company’s stock worth $496,000 after acquiring an additional 28,094 shares during the period. Finally, Congress Asset Management Co. increased its position in shares of Alphatec by 20.7% during the third quarter. Congress Asset Management Co. now owns 532,069 shares of the medical technology company’s stock worth $5,491,000 after acquiring an additional 91,431 shares during the period. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Key Headlines Impacting Alphatec

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Third-quarter revenue increased 12.6% year over year to approximately $221.2 million, while earnings of $0.09 per share improved from $0.03 a year earlier. Management continues to target a 16% adjusted EBITDA margin for 2026. Alphatec third-quarter results
• Positive Sentiment: Wells Fargo lowered its price target from $14 to $12 but maintained an “overweight” rating, implying substantial potential upside if Alphatec stabilizes growth and executes on its profitability plans. Wells Fargo rating
• Neutral Sentiment: Analyst expectations remain divided: BMO Capital Markets downgraded the stock to “market perform” with an $8 price target, while other analysts continue to see valuation upside. BMO Capital Markets rating
• Negative Sentiment: Alphatec reduced its 2026 revenue outlook to approximately $862 million from roughly $882 million, below the prior market expectation. Management cited fewer surgeons purchasing its bone-graft products used in spinal-fusion procedures. Alphatec guidance reduction
• Negative Sentiment: Third-quarter adjusted earnings of $0.09 per share and revenue of $221.2 million both missed analyst estimates, reinforcing concerns about slowing demand despite year-over-year growth. Alphatec earnings miss
• Negative Sentiment: Levi & Korsinsky and Ademi LLP announced investigations into potential securities-law violations related to Alphatec’s outlook and subsequent decline. These notices may add reputational and legal risk, although they do not establish wrongdoing. Alphatec investor investigation

About Alphatec

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.